CD4 and neoplasm: We demonstrate in the tumor microenvironment that Listeria-based immunotherapy when combined with agonist anti-GITR Ab enhances both the CD8+ T cells as well as the number of non-Treg CD4+ T cells resulting in enhanced therapeutic effector cell/suppressor cell ratios.